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Successful drug delivery using implantable pumps may be found in over 12,500 published
articles.Their versatility in delivering continuous infusion, intermittent or complex infusion
protocols acutely or chronically has made them ubiquitous in drug discovery and basic
research.The recent availability of iPRECIO®, a programmable, reﬁllable, and implantable
infusion pump has made it possible to carry out quantitative pharmacology (PKPD) in sin-
gle animals.When combined with specialized catheters, speciﬁc administration sites have
been selected. When combined with radiotelemetry, the physiologic gold standard, more
sensitiveandpowerfulmeansofdetectingdruginducedtherapeutic,and/oradverseeffects
has been possible. Numerous application examples are cited from iPRECIO® use in Japan,
United States, and Europe with iPRECIO® as an enabling drug delivery device where the
reﬁllable and programmability functionality were key beneﬁts.The ability to start/stop drug
delivery and to have control periods prior dosing made it possible to have equivalent effects
at a much lower dose than previously studied. Five different iPRECIO® applications are
described in detail with references to the original work where the implantable, reﬁllable,
and programmable beneﬁts are demonstrated with their different end-points.
Keywords: drug delivery, mini pump, osmotic pumps, implantable pump, dose response, quantitative pharmacol-
ogy, preclinical, telemetry
INTRODUCTION
Following a landmark report in 1990 that stated 40% of com-
poundsfailedclinicaltrialsbecauseof pharmacokinetics(PK),the
pharmaceutical industry responded by integrating drug metabo-
lism and pharmacokinetic (DMPK) scientists earlier in the drug
discovery process with good success (Korfmacher, 2009). Today,
thepharmacologicalindustrycontinuestolookforwaystoreduce
drugcandidateattritionthroughoutthedrugdiscoveryanddevel-
opment process, where unforeseen efﬁcacy and safety issues are
currently cited as the cause of continually high attrition rates
(Walker, 2004; Mass et al., 2007; Wehling, 2009; Wendler and
Wehling, 2010; Wittenburg and Gustafson, 2011). In the past two
decades,drugdiscoveryhasgonethroughsigniﬁcantchangeswith
the advent of genomics, combinatorial chemistry, computational
modeling, and proteomics. An unprecedented abundance of tar-
gets and compounds have also contributed to a fundamental shift
in evaluation of pharmaceutical properties and impact of such
properties on drug development (Neervannan, 2006).
Morerecently,quantitativepharmacologyorpharmacokinetics–
pharmacodynamics (PK/PD) has recently become a major theme
in many pharmaceutical research organizations, and a key part of
thedrugdiscoveryprocess(VanDerGraaf andGabrielsson,2009).
The integration of PK and PD has made it possible to character-
ize the onset, intensity, and duration of a drug’s pharmacological
effects and relate these effects to the drug’s mechanism of action
(Gabrielsson et al., 2010).
Preclinical/non-clinicalformulationsanddrugdeliveryarevery
important in order to support early in vivo studies efﬁciently and
productively.As part of the discovery team,formulation scientists
and medicinal chemists are required to ensure that new molecular
entities (NME) are developed that optimize compound exposure
with acceptable PK/PD and toxicologic results. Example successes
resulting from this close collaboration between formulation sci-
entists and discovery teams are cited in “strategies for bringing
drug delivery tools into discovery” (Kwong et al., 2011). Obtain-
ing meaningful data/information early in the discovery process
elevates the best NME to the preclinical stage with the highest
probabilityof successfullyreachingthemarketplace(Neervannan,
2006; Kwong et al., 2011).
Withtheplethoraofnewtargets,optimizedstructuresandgood
formulations in early discovery, drug discovery programs are also
exploring new ways to validate the targets in vivo (Neervannan,
2006) especially since PD studies typically are longer in duration
and often require chronic administration/repeat dose (Mass et al.,
2007).
DRUG DELIVERY
Implantablepumpshavebecomeaveryconvenientandcosteffec-
tive method to deliver drugs for biochemical research in the phar-
maceuticalindustry.Theyarealsointheirownrightanimportant
research tool for investigating continuous infusion versus the typ-
ical peak to trough exposure proﬁles of bolus injections. Further,
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this method has signiﬁcant animal welfare beneﬁts over repeat
dosing by other routes where restraint and tethered infusion or
injection may be required (Anonymous, 2001). With the use of
specialized catheters,speciﬁc administration sites may be selected
includingICV(bypassingthebloodbrainbarrier),intrathecal,IV,
SC, and IP. Animal handling artifacts are also reduced to a mini-
mum. A further advantage of using an implantable pump is that
it allows different absorption proﬁles to be mimicked when infus-
ing intravenously (Van Der Graaf and Gabrielsson, 2009). This
characteristic is especially useful since the modeling of the proﬁle
of the plasma exposure achieved with intended therapeutic route
often still requires the use of intravenous infusions.
Over 12,500 published studies demonstrate that implantable
pumps reliably deliver a wide range of test agents (vehicles
and active compounds) Anonymous (2011a). These implantable
pumpsarepassivedeviceswhichdeliveracontinuousinfusionﬂow
based on the model of the pump and osmotic pressures. There are
12pumpmodelswith9differentinfusionﬂow-rateswiththelow-
estat0.11μl/handthehighestat10μl/h.Infusiondurationsstart
from 1day to a maximum of 6weeks. These implantable pumps
are typically used in “early proof of concept studies,” in appli-
cations where the half-life of the molecule is very short, and in
continuous infusion applications (Neervannan, 2006).
In addition to the 12,500 published studies, comprehensive
formulationreviewsandarticleshighlightingvehicle/solventcom-
binations have been published (Lee et al., 2003; Strickley, 2004,
2008;Gadetal.,2006;LiandZhao,2007;Massetal.,2007;Palucki
etal.,2010)andthesewillaidtheusertoformulatecompatibleand
stable formulations for drug delivery. Further,there is an excellent
review article (Gad et al., 2006) which lists many formulations
used in preclinical toxicology studies. These publications, along
with the commercially available kits for testing compatibility of
active compounds and vehicles for implantable pumps,will make
it easier for researchers to verify and utilize implantable pumps.
PUMP ADVANTAGES ANONYMOUS (2011a,b) OVER OTHER
SELECTED METHODS OF ADMINISTRATION
• Ensure around-the-clock exposure to test agents at predictable
levels.
• Permitcontinuousadministrationofshorthalf-lifeproteinsand
peptides.
• Provide a convenient method for the chronic dosing of labora-
tory animals.
• Minimize unwanted experimental variables and ensure repro-
ducible, consistent results.
• Eliminate the need for nighttime or weekend dosing.
• Reduce handling and stress to laboratory animals.
• Small enough for use in mice or very young rats.
• Allow for targeted delivery of agents to virtually any tissue.
• Serve as cost–effective research tools.
Since March 2007,iPRECIO® infusion pumps have been an alter-
native choice to the Alzet® Osmotic Pumps (Durect®, Cupertino,
CA, USA). iPRECIO® is an infusion pump based on a miniature
peristaltic action. It is a self-contained intelligent device con-
sisting of a microcontroller with associated memory, embedded
software, inputs/outputs, a micro pulse stepping motor, crystal
oscillators, electronic circuitry, and a battery power source. Once
programmed and activated, the infusion pump operates inde-
pendently following its protocol. The embedded software in the
microcontroller is programmed via a PC-based software platform
(Abe et al., 2009; Tan and Tsuru, 2009). See Figure 1 for a picture
of iPRECIO® Micro Infusion Pump.
iPRECIO® brings a whole new level of sophistication to
implantable lab animal infusion pump where it is both program-
mable and reﬁllable. Key features of iPRECIO® pumps are brieﬂy
summarized in Figure 2 where circadian rhythm, dose response,
bolus infusion protocols are programmable. Full description of
speciﬁcations can be found on www.iprecio.com and in the
references (Abe et al., 2009; Tan and Tsuru, 2009).
FIGURE 1 | iPRECIO
® SMP-200, 2nd generation implantable, reﬁllable and
programmable pump for small laboratory animals based on a
mini-peristalsis ﬂow infusion mechanism.
FIGURE 2 | Summary of the key features of the 2nd generation iPRECIO
®
Pumps reproduced from the current SMP-200 product brochure.
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To date (Anonymous, 2011c), the majority of applications in
Japan have been the use of iPRECIO® with a constant infusion
rate with ±5% accuracy (speciﬁcation of the pump) following
a recovery period (after implantation) with constant dose infu-
sion. For example, Yamato et al. (2010) used iPRECIO® as an
enabling technology to allow baseline activity to be monitored
after implantation of pump with brain infusion cannula in place
while it only infused vehicle/solvent. (Yamato et al., 2010)T h e
effect of agent/drug on animal activity compared to its baseline
couldthenbeanalyzedwithouttheeffectof handlingandanesthe-
sia.Thesetypesof applicationsuseonlythemostbasiccapabilities
of the pump; speciﬁcally start, stop, duration, infusion ﬂow-rate,
and the possibility to reﬁll/exchange agents without additional
surgery. Even so, the possibility to allow the animal to recover
fully to normal physiological conditions prior to accurate infu-
sion of drug at programmed time points have been a compelling
reﬁnement for the researchers to adopt iPRECIO®. Table 1 sum-
marizesselectedexampleuseof iPRECIO®inJapan.Thesepumps
have mainly been used in rats but have also been used in goat,
non-human primates,rabbits,and guinea pigs. Due to iPRECIO®
pumps small size, good accuracy and functionality, they have also
been used with mice with a tether system where they replaced
the syringe pump. With such a compact system; animal, cage,
and pump may be isolated very easily, for example isolated and
metabolic cages.
More sophisticated and advanced infusion protocols have been
evaluated by using the programmable nature of the iPRECIO®
pumps (Abe et al., 2009) where dose response of Ang II was
Table 1 | Selected examples of iPRECIO® applications in Japan with details of species, agent/drug, administration site, and infusion protocol.
Customer Animal Drug Administration route Mode Flow-rate (μl/h)
Pharmaceutical Company Rat The toxicity test of a circulation
related medicine
External jugular vein Conﬁdential Conﬁdential
Pharmaceutical Company Rat Reproductive hormone External jugular vein RCV/constant 5–10
Pharmaceutical Company Rat Diabetes related medicine External jugular vein RCV/variable 3–15
Pharmaceutical Company Rat Epilepsy related medicine Injection in the skull RCV/constant 1–10
Pharmaceutical Company Rat Antiphlogistic–sedative–drug
relation
Subcutaneous RCV/Constant 1–20
Pharmaceutical Company Rat Ophthalmology region medicine Fundus oculi RCV/constant 3–15
Pharmaceutical Company Rat Metabolism related External jugular vein RCV/constant 5–10
Pharmaceutical Company Rat pH5 strong acidity solution Subcutaneous Conﬁdential Conﬁdential
Fukuyama University Rat Pain Subcutaneous Conﬁdential Conﬁdential
Gifu university Rat Angiotensin 2 losartan External jugular vein Instant/variable 3–30
Hoshi University Hamster Conﬁdential External jugular vein and
Subcutaneous
RCV/constant 1–15
Hoshi University Rat Conﬁdential External jugular vein RCV/constant 5–30
Hoshi University Rat Pain clinic related Hypodermoclysis RCV/constant 1–30
Jichi Medical University Mouse Conﬁdential Subcutaneous Conﬁdential Conﬁdential
Nagoya City University Rat Angiotensin II External jugular vein Conﬁdential Conﬁdential
National Institute of Agro
biological Sciences
Goat Conﬁdential Vein RCV/constant 5–30
National Center of Neurology
and Psychiatry (NCNP)
Mouse Conﬁdential Subcutaneous RCV/constant 1–15
Nihon University Rat Conﬁdential External jugular vein RCV/constant 3–10
Osaka City University Rat Neurotransmitter Injection in the skull RCV/constant 1–15
Osaka University of
Pharmaceutical Sciences
Rat Vitamin B12 External jugular vein Conﬁdential Conﬁdential
Shiga University of Medical
Science
Conﬁdential Reproduction related Subcutaneous Instant/variable 1–7
Shiga University of Medical
Science
Rat Reproductive hormone External jugular vein RCV/constant 5–10
Tokyo Women’s Medical
University (TWMU)
Hamster Conﬁdential External jugular vein and
Subcutaneous
RCV/constant 1–15
The University ofTokyo Rat Nicotine External jugular vein Conﬁdential Conﬁdential
The University ofTokyo Rat Conﬁdential External jugular vein RCV/constant 5–15
RCV Mode is a function of iPRECIO
® pumps which allow saline to be infused initially during the recovery period prior to agent administration. At the appropriate time,
saline is replaced with agent to allow the programmed start time taking into account dead volumes within the infusion system.
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investigated along with effect of Losartan infusion in a second
pump.
Matsuoka et al. (2007) used iPRECIO® pumps to administer
vitamin B12 at onset of the light cycle and at the onset of the dark
cycle to study the effect B12 on the arousal and body temperature
rhythm.
Shobo et al. (2010, 2011) used iPRECIO® as an enabling tech-
nology to continuously administer olanzapine® chronically to
maintain higher exposure levels and with more stability than any
other published reports (ﬁve cited) to induce adiposity in male
rats.
InJuly2009,asecondgenerationiPRECIO®pumpwasreleased
in smaller package (30% smaller by volume), infrared communi-
cations replaced metallic contact pins for download/activation,
improved septum port design to facilitate ﬁlling/reﬁlling in vivo
for up to 50 operations and new repeat function to allow the 10
ﬂow-steps to be increased to 2,500 steps. These new devices are
now being used extensively both domestically in Japan and inter-
nationally worldwide. Recent selected research publications using
these devices are:
(1) “Vestibular-mediated increase in central serotonin plays an
important role in hyper gravity-induced hypophagia in rats”
(Abe et al., 2010).
(2) “GPR54 agonists a way forward for down regulation of the
GnRH pathway?”(Douglas et al.,2011).
(3) “Extracellular protein phosphorylation promotes functional
recovery from experimental spinal cord injury” (Yoshinori,
2011).
(4) “Use of novel programmable pump for intra cranial admin-
istration in orthotopic glioblastoma tumor models in rats”
(Schnell and Ferrat,2011).
(5) “Reﬁned rat pharmacology studies with infusion using
implantable pumps”(Martel,2011).
(6) “Implantable infusion pumps for chronic rodent studies”
(Osborn et al., 2011).
Advantages cited re-emphasized our Japanese use experience
whereiPRECIO®allowedacontrolresponsetobeobtainedbefore
a long infusion of substances of interest begins. Further advan-
tages cited were that it was possible to have a single surgery for
bothtumorcellinjectionandpumpimplantation(salineinfusion
initially). The ﬂexibility then to go from saline infusion to infu-
sion of therapeutic at a researcher/operator deﬁned time which is
relatedtoclinicalsignsand/ortumorsize,byreﬁllingthereservoir
with the substance was also cited as an advantage.
Morerecently,intermittentinfusionsandbolusinjection(s)per
day (24h cycles) have been of strong of interest to iPRECIO®
users.An example for the former,Davis et al. (2010) used 0.2μl/h
for 48h to simulate stopping cycles which acted as control peri-
ods for the dose response study of 5-HT infusion. Good results
were obtained with a clear dose response dependency with con-
trol periods of mean arterial pressure (MAP). For more details
see example 3 later within this article. For an example of the
latter, iPRECIO® pumps have been referenced as a great poten-
tial/promise of dramatic changes of the microinjection paradigm
forneurosciencewhere50–100nlaremostcommonincurrentrat
studies (Zaretskya et al.,2011).
Internally, we have been able to conﬁrm that the accuracy
of iPRECIO® pumps remained within ±5% for total volume
infused (bolus). Tests are continuing, with results obtained for
60 continuous days. Test parameters were to infuse a single bolus
of 15μl/day with different infusion/bolus rates; 5μl/h for 3h,
10μl/h for 1.5h, 20μl/h for 0.75h, and 30μl/h for 0.5h. For
the rest of the 24h period, the iPRECIO® pumps were pro-
grammed to infuse 0μl/h. Total of 12 pumps were used, 3 per
bolus ﬂow-rate.
The most recent and additional iPRECIO® references may be
found at http://www.iprecio.com/support/index.html
PAIRED DATA SETS
Thereﬁllableandprogrammablenatureof iPRECIO®allowseach
rat to be its own control especially if terminal end-points are not
requiredforthetreatments.Thiswouldbeamorepowerfultestof
difference because the variance between subsamples is lower than
the variance between independent samples (Kenakin, 2009).
After recovery from the implantation of the pump, baseline
physiological and behavior information may be obtained prior to
drug administration and then followed by escalation study com-
prising vehicle,low dose,medium dose,and high dose. Therefore,
instead of having groups of ﬁve animals per treatment,it could be
possible to have one group of animals subjected to a sequence of
treatments (with washout period if necessary) without additional
surgery and with minimum handling. This would signiﬁcantly
reduce the required number of animals while giving a more pow-
erful test of difference as the same animals are subjected to the
different treatments.
SUPERIOR TELEMETRIC STUDIES WHEN COMBINED WITH
USE OF iPRECIO® PUMP
Radiotelemetry (telemetry) has become the gold standard for
monitoring physiological data in unrestrained, conscious labo-
ratory animals. The physiological parameters measured through
telemetry include mean arterial blood pressure,heart rate activity,
and temperature, to name a few. The use of stress-free laboratory
animals leads to higher sensitivity for drug induced effects and
lower variability of parameters measured. In combination with
this gold standard,sophisticated implantable infusion pumps will
lead to ever more sensitive and powerful means of detecting drug
induced therapeutic and/or adverse effects.
EXAMPLE USES OF iPRECIO®
The next section of this technology article summarizes both
published data and data provided by personal communication
with iPRECIO® users. These applications will be referenced
accordingly.
1. Dependence and withdrawal in the same cohort.
2. Rapid and long term delivery of drug with radiotelemetry
(blood pressure endpoint).
3. Dose response curve within an individual animal with
radiotelemetry (blood pressure endpoint).
4. Dose response of multiple drugs, within a single animal with
radiotelemetry (systemic and ventricular pressure endpoints).
5. Drug exposure levels in blood for three dose proﬁles (PK).
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1 Dependence and withdrawal in the same cohort
For the ﬁrst time, a physical dependence and withdrawal (PDW)
study could be carried out with unrestrained freely moving ani-
mals (as opposed to tethering) for a vehicle, constant dose and
escalation dose group of pentobarbital. Constant dose is where
the pump was programmed to infuse at ﬁxed dose and esca-
lation dose is where the pump was programmed to infuse an
increasing dose. Functional Observation Battery,food self admin-
istration(SA),bodytemperatureandbodyweightweremonitored
onbaselineday1,throughouttheinfusionperiod(days1–14)and
withdrawal (days 15–21). This was made possible with the use of
the implantable, programmable and reﬁllable iPRECIO® pumps.
Summary of results are shown in Table 2 and Figure 3.
Coles et al. (2010) successfully characterized an escalating
sodium pentobarbital regime as a positive control in this PDW
model using iPRECIO®.
2 Rapid and long term delivery of drug with radiotelemetry
(blood pressure endpoint).
Seitz et al. (personal communication)1 recently evaluated
iPRECIO® pumps as an Ang II drug delivery system respect to
existing technology, namely the Alzet® osmotic pump (Durect®,
Cupertino, CA, USA). The authors, have extensive experience
in infusion of angiotensin II to produce chronic hypertension
(assessed by DSI radiotelemetric measurements).
iPRECIO® pumps were found to be reliable and easy to use.
Their reliability appears to exceed that of osmotic pumps, based
onthelevelofbloodpressureproducedduringangiotensinIIinfu-
sion. The pumps were well tolerated for long periods. Results for
Ang II infusion with Alzet® osmotic pumps and iPRECIO® are
shown in Figures 4 and 5 respectively.
3 Dose response curve within an individual animal with
radiotelemetry (blood pressure endpoint).
(Davis et al. (2010) previously established, using both the
iPRECIO® micro infusion pump and radiotelemetry devices,
1http://www.datasci.com/pdf/information/CaseStudy_iPRECIO%20Comparison.pdf
Table 2 | Clinical signs observed during dosing and withdrawal
following pentobarbital and vehicle.
Day Hours Vehicle Pentobarbital
constant
Pentobarbital
escalation
D2 26 – ↓ Body tone –
D13 290 – – ↓ Handling reactivity
↓ body tone*
↓ ataxia
D14 314 – – ↓ Body tone
W15 338 – – Straub tail*
*p≤0.05 compared to vehicle.
that 5-HT administration produced repeated falls in blood pres-
sure in the sham (normotensive) and deoxycorticosterone acetate
(DOCA)–salt (hypertensive) rat when the pump was turned on.
Whenthepumpwasturnedoff(0.2μl/h),bloodpressurereturned
to normal. This study demonstrated that an equivalent effect
was possible at a much lower dose than was previously stud-
ied (25μg/serotonin hydrochloride/kg/min) in the sham and
DOCA–salt rat.
Additionally,for the ﬁrst time,a 5-HT dose response study was
carried out in a single animal with unrestrained movement using
radiotelemetry devices and the iPRECIO® micro infusion pump.
This study demonstrated that increasing concentrations of 5-HT
(1, 5, 15μg/kg/min) produced correspondingly greater falls in
FIGURE3|( A – C ) . Food self administration break point reached, body
temperature, and body weight following chronic pentobarbital or vehicle
B=baseline, D=dosing, W=withdrawal, *=p ≤0.05 compared to vehicle,
dotted line=anesthesia for pump loading. Points represent mean±SEM.
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bloodpressureinthenormotensiveSpragueDawleyrat(Figure6).
Heartrate(HR)wasalsoelevatedfollowingeachadministrationof
5-HT (1, 5, 15μg/kg/min; Figure 7). The programmable feature
of iPRECIO® pump also allowed baseline measurements to be
made after the implantation but prior to 5-HT infusion. Addi-
tionally, L-NNA administered in the drinking water when the
iPRECIO® pump was turned off raised blood pressure in these
rats and prevented a subsequent fall in blood pressure when the
pump was turned on (5-HT – 15μg/kg/min).
In summary, the observation of a lower threshold for induc-
ing a 5-HT-induced fall in blood pressure, and the creation of a
FIGURE 4 | iPRECIO
® appeared to initiate hypertension more rapidly, and
maintained a higher level of arterial pressure than the Alzet
® pump. Points
represent means±SEM for number of animals indicated in parentheses
(n). Vertical line indicates beginning of Angiotensin II infusion.
dose response curve in a single experiment would not have been
possible using a traditional osmotic drug delivery device. Thus,
theiPRECIO®microinfusionpumpmayoffersigniﬁcantbeneﬁts
to investigators.
GOLD STANDARD CARDIOVASCULAR APPLICATION USING
iPRECIO® AND RADIOTELEMETRY TO HAVE MAXIMUM
SENSITIVITY
4 Dose response of multiple drugs, within a single animal with
radiotelemetry(systemicandventricularpressureendpoints).
For the ﬁrst time, both systemic and ventricular pressure in the
rat could be evaluated in a free moving animal model using
radiotelemetry and iPRECIO® pumps (Gizzi et al.,2011a,b). Four
(4) animals were instrumented with transmitters for left ventricu-
larpressuremonitoring(DSI-TA11PA-C10)andaorticbloodpres-
suremonitoring(DSI-TA11PA-C40).Thenafterarecoveryperiod,
Baird et al. (personal communication) administered each animal
sequentially with vehicle (0.9% sodium chloride for injection,
USP), dobutamine, and verapamil using the iPRECIO® pumps.
Dobutamineisasyntheticcatecholaminewithpositiveionotropic
activity which is used therapeutically to increase cardiac output,
via an ionotropic mechanism. Paradoxically,it produces relatively
little change (increase) in HR rate and exhibits lusitropic activity.
Verapamil is an antiarrhythmic phenylalkylamine which blocks
ioniccurrentacrossL-typevoltagegatedcalciumchannelscausing
variable effects on HR (depending on the chronicity of exposure),
decreased conduction through SA and AV node tissues,decreased
contractility, peripheral vasodilation, increased coronary blood
ﬂow, and decreases in myocardial oxygen demand.
Details of the infusion protocol are shown in Table 3. Treat-
ments 1, 2, and 3 were administered to the same four animals
FIGURE 5 | While the Alzet
® pump (Figure 4) could only be used for 14days, the iPRECIO
® pump (same infusion ﬂow-rate as Alzet
®), after transcutaneous
reﬁlls, maintained an elevated level of arterial pressure.There are longer duration Alzet
® pumps but they operate with a lower infusion rate. iPRECIO
® pumps
will infuse for up to 6months at 1μl/h.The longest duration Alzet
® pump would only infuse for 6weeks.
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FIGURE 6 | Effects of increasing doses of 5-HT on mean arterial pressure
(MAP) in male Sprague Dawley rats. Points represent mean±SEM for ﬁve
(5) animals.Time is represented by days on the x-axis. S represents days of
5-HT infusion. *Statistically signiﬁcant (p <0.05) difference compared to
control BP . †Statistically signiﬁcant (p <0.05) difference compared to blood
pressure following L -NNA administration. Boxes represent window of time
during which 5-HT infusion was on.
FIGURE 7 | Effects of increasing doses of 5-HT on mean heart rate (HR) in
male Sprague Dawley. Points represent mean±SEM for ﬁve (5) animals.
Time is represented by days on the x-axis. S represents days of 5-HT
infusion. *Statistically signiﬁcant (p <0.05) difference from control heart
rate. Horizontal bracketed bars indicate the time window over which 5-HT
infusion was on.
withtheappropriatewashoutperiods.Eachtreatmentwasadmin-
istered stepwise (low to high dose) at four infusion rates, and
Table 3 | Treatments and dose details used in the study for saline,
dobutamine, and verapamil HCl.
Treatment Vehicle/positive
control article
μg/kg/min Cardiovascular
parameters (left
ventricular and
aortic pressure)
Number of
animals
(male)
1 Saline 0 4
2 Dobutamine 1, 3, 10, 30 4
3 Verapamil HCl 100, 180, 320, 560 4
the duration of each individual rate/exposure was approximately
1.5h. The vehicle was administered at rates equivalent to those
programmed during the verapamil exposures. Doses of dobut-
amine was prepared individually for each animal based on that
animal’s body weight taken on the day prior to dose preparation.
Within each designated treatment condition,temporally contigu-
ous ventricular and aortic pressures (in addition to HR and other
derivedparametersasindicatedbelow),wererecordedatleastonce
every 15min during the course of the infusions, for a total of six
segments of data collected for each transmitter per dose.
Results are shown in Figures 8 and 9. iPRECIO® pumps suc-
cessfully infused successive doses of the three treatments. The
effect of dobutamine and verapamil were consistent with their
pharmacology across their selected dose ranges for continuous
infusion because they caused an:
• increase in LV contractility estimate, slight increase in HR
(data not shown), no change in systemic arterial pressure for
dobutamine.
• decrease in LV systolic and developed pressures, decreased LV
contractility estimate and systolic arterial pressure, and lack of
change in HR (data not shown) for verapamil.
5 Drug exposure levels in blood for three dose proﬁles (PK)
Fortheﬁrsttime,theadvantagesandrelevanceofiPRECIO®micro
infusion pumps to perform pharmacokinetic experiments in rats
requiring intravenous infusion at low infusion rates,low dose vol-
umewithrepeatedinfusionsessioninthesameanimaloverseveral
weeks and using a pharmacological substance (i.e.,Valsartan®) is
demonstrated in detail. The study involved one (1) group of ﬁve
(5) male Wistar rats weighing between 404.6 and 459.9g on the
day of the implantation. Blood samples were collected from fed
animals.Figure10andTables4and5describethestudyprotocol.
TheValsartan®exposurelevelsareshowninFigures11and12.
Figure11showsthemeanplasmavaluesforthethreedoses.These
resultsshowedthattheplasmaexposureweredose-dependentand
lessthandoseproportional,especiallyat1and4hafterthestartof
theinfusion(around×2.5and×7.8theexposurereachedat3μl/h
for24h,andaround×3,and×7.1at4h).Valsartan®plasmaexpo-
sure for the 10μl/h for 5h infusion showed that levels dropped
rapidly after the stopping of the infusion, i.e., 5h after the start.
At 23h post-dosing, the plasma exposure was at the low limit of
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FIGURE 8 | Shows results for arterial systolic pressure for the three different treatments. Arterial systolic pressure was decreased by administration of
successive doses of verapamil; arterial systolic pressure was unaffected by successive doses of dobutamine; points represent means±SEM.
FIGURE 9 | Shows results for LV contractility respectively for the three different treatments. LV contractility was increased by successive doses of dobutamine.
LV contractility was decreased by administration of successive doses of verapamil. Points represent means±SEM.
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Table 4 | Brief summary of study protocol.
Recovery period Dosing Recovery and washout Dosing Recovery and washout Dosing Total
1week 30μl/h for 24h 2weeks 3μl/h for 24h 2weeks 10μl/h for 5h 37days
Acclima za on 1 week Recovery 
Period 3μl/hr saline 
30 μl/hour Valsartan 
infusion for 24 hours
• Replace with Valsartan
• Flush dead volume
• Valsartan 
Administra on
• Vehicle infusion for 24 
hours
• Saline infusion
2 week Recovery 
Period 3μl/hr saline 
3 μl/hour Valsartan 
infusion for 24 hours
• Replace with Valsartan
• Flush dead volume
• Valsartan 
Administra on
• Vehicle infusion for 24 
hours
• Saline infusion
2 week Recovery 
Period 3μl/hr saline 
10 μl/hour Valsartan 
infusion for 5 hours
• Replace with Valsartan
• Flush dead volume
• Valsartan 
Administra on
• Vehicle infusion for 24 
hours
•S a l i n e  i n f u s i o n
37 days
FIGURE 10 | Brief description of study protocol for Valsartan
® infusion and blood sampling. More detailed descriptions are shown inTables 4 and 5.
FIGURE 11 | Valsartan
® plasma exposure for the three doses.
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quantiﬁcation (LLQ) or at the low limit of detection (LLD) in all
animals.
At the 30μl/h infusion rate as shown in Figure 12, plasma
concentrationsachievedinthedifferentanimalswerequiterepro-
ducible, except in Animal No. 201002027 which displayed a very
low plasma level at the 23h time point. This discrepancy was not
attributable to an infusion abnormality because the actual vol-
umes administered (measured) in all the animals were consistent
and close to the theoretical infusion volumes expected as shown
in Table 6 below.
The results showed that all the animals were exposed to Val-
sartan® in a dose-dependent manner with respect to infusion
ﬂow-rates and ﬁlling/extracting/reﬁlling procedures with saline,
Valsartan®, and vehicle. Valsartan® was successfully administered
withiPRECIO®pumpsoverastudylasting37dayswithhighdose
(24h30μl/h),lowdose(24h3μl/h)andmid-dosewithastop(5h
10μl/h). These results are consistent with published Valsartan®
exposure data.
The full study report is available from Primetech.
OVERALL DISCUSSIONS AND CONCLUSION
The“fail early; fail economically”model seems to be a continuing
trend for Big Pharma. It requires the front loading of drug dis-
covery with safety and efﬁcacy studies to select and prioritize the
most promising agents from the abundance of NMEs to enter the
preclinical development stage. This in turn requires better formu-
lationsandcosteffectivedrugdeliverysolutionstomaximizeexpo-
sure for PKPD andADME studies. More recently,even innovative
drug delivery systems primarily used with approved drugs, have
been used in the preclinical environment for difﬁcult to deliver
FIGURE 12 | Individual data for 30μI/h Valsartan
® exposure.
Table 6 | Individual data for infusion veriﬁcation and validation for the 30μl/hValsartan® infusion.
Animal number Filled Programmed Remaining
(theoretical)
Remaining
(extracted)
Volume administered
(measured)
Difference
(volume administered)
% Difference
(volume administered)
201001586 900 755.4 144.6 170 730 −25.4 −3.36
201001587 900 755.4 144.6 140 760 4.6 0.61
201001588 900 755 145 150 750 −5 −0.66
201002026 900 756 144 120 780 24 3.17
201002027 900 756 144 180 720 −36 −4.76
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agents and challenging half-life molecules (Rosen and Abribat,
2005).
Implantable pumps and especially sophisticated implantable
pumps like iPRECIO® will allow cost effective PD studies and
repeat dose studies to be carried out and will allow for new
ways to validate the target in vivo. Over 12,500 studies demon-
strating the reliable use of implantable pumps to deliver a wide
range of test agents have been published. The various summaries
and detailed examples highlighted within this technology article
demonstrated the clear advantages of an active programmable,
reﬁllable, and implantable device versus a passive device. With a
reliable,convenient,and cost effective method to carry out PKPD
studies in vivo in non-clinical studies, the reality of extrapolation
of the essentials in PKPD will be possible. These extrapolations
will facilitate the important translation from animal to human
testing (Neervannan, 2006). A holistic understanding of NME,
formulation vehicle, dose, exposures, and concomitant efﬁcacy
enables scientists to better correlate study outcomes with pro-
vided test articles and thus, carve a development path forward
withsigniﬁcantimplicationstodownstreamsuccessoftheproduct
(Kwong et al., 2011).
The industry is also focusing on science based understanding
of the mechanism of action. We believe that the iPRECIO® infu-
sion pump with its programmable and reﬁllable features would
allow quantitative pharmacology, PKPD in a free moving animal
model which would allow greater understanding of the mecha-
nisms in a cost effective manner. In addition, facilitate the inves-
tigation and commercialization of new chronopharmaceuticals to
add to those currently in the market.“Drug delivery technologies
for chronotherapeutic applications” reviewed circadian rhythm
in various disease states including cancer and the cardiovascular
system (Khan et al.,2009).
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